Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Ten unbeatable reasons to explore a career with Oxford PharmaGenesis in 2022

It’s a new year, and a time when many people reflect on whether their role is providing the opportunities, enjoyment and sense of purpose that they deserve. If this sounds...

Oxford PharmaGenesis

- PMLiVE

Amgen’s Lumykras receives conditional marketing authorisation from EC

The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation

- PMLiVE

Discovering the unique power of DOLs – are you harnessing the power of pharma’s new educators?

By Akarsh Sakalaspur

- PMLiVE

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies

The strategic research collaboration between the two companies aims to develop AI-driven pipeline of precision-engineered therapies

Digitizing Cardiac Rehab to Capture and Retain More Patients

Dr. Harsh Vathsangam, CEO & Co-Founder of Moving Analytics, shares his expertise on mobile health and discusses how it can be used to improve patient adherence and access to cardiac...

Impetus Digital

What if pharma engaged its customers like Netflix or Amazon?

By Lorraine Walters

- PMLiVE

Pfizer/BioNTech confirm new global collaboration to develop first mRNA-based shingles vaccine

The companies plan to begin clinical trials of the new vaccine in the second half of 2022

- PMLiVE

Omnichannel marketing – more than a buzzword

By Dimitri Challouma and Dominic Cleall

NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE

With a stormy outlook predicted for health and care, Wilmington Healthcare’s Oli Hudson looks at the five critical shifts that pharma should focus on as it navigates its way through...

Wilmington Healthcare

- PMLiVE

After the wildfire: how will healthcare recover from the pandemic?

Following a forest fire, the natural world recovers according to predictable patterns, in a process known as ‘ecological succession’. After the global conflagration of COVID-19, what will the equivalent patterns...

- PMLiVE

Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy

The licence is worldwide and exclusive and may include future royalty payments

- PMLiVE

UK marks one-year anniversary of Oxford/AstraZeneca vaccine

The at-cost vaccine produced in the UK has been administered worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links